Next September, the first-ever United Nations summit on non-communicable diseases will be held. It is a prime opportunity to elevate chronic disease on the global agenda. And it’s a life or death decision for the world’s human and economic health.
See what's happening, who's talking and what will be making headlines on Friday's Squawk on the Street.
In a snapshot of systemic waste, researchers have calculated that more than half of the 354 million doctor visits made each year for acute medical care, like for fevers, stomachaches and coughs, are not with a patient’s primary physician, and that more than a quarter take place in hospital emergency rooms. The NYT reports.
President Obama faces a messy political fight over the federal court ruling striking down his new, looser policy letting federal grant money pay for stem cell research involving “destroyed” embryos.
Why the “Mad Money” host has faith in this pharmacy-benefit manager, even though the market may not.
Medical tourism, family travel and international migration have combined to import a potent new form of antibiotic resistance halfway around the planet—and the physician-researchers who have tracked its rapid spread say it is already on the verge of becoming untreatable.
Baby Boomers want to live longer and to live better. The convergence of Boomer expectations and technology is forging a disruptive force that will improve life tomorrow for everyone.
Two reports published Friday offer novel approaches to the age-old dream of regenerating the body from its own cells.
Unsafe drinking water is the world’s largest cause of disease and death. The United Nations Development Program has stated that every $1 invested in water and sanitation produces $9 in healthcare cost reduction and economic development.
Health care spending both contributes to our current economic difficulties and provides us with a potential opportunity to help solve them. It is a great burden on companies, while at the same time it is helping create jobs.
Here's why you should keep a close eye on these six stocks.
The drug maker reported Friday a quarterly operating profit that topped Wall Street expectations and issued full-year guidance in line with current forecasts, but sales were slightly below the consensus estimate.
If Sanofi moves ahead with an unsolicited offer for Genzyme, there will be plenty of biotech investors and investment bankers shaking their heads in wonderment, particularly if it is at a price well above Genzyme’s current level.
The very large French pharmaceutical company made an informal acquisition approach to Genzyme. That approach was essentially rebuffed and not met with any significant talks, according to people familiar with the matter. However, especially in recent days, talks have been heating up.
Counterfeiters have created an international, multi-billion-dollar industry by making cheap imitations of designer goods and selling them for a fraction of the price.
Today's six stocks worth watching.
The last thing anyone checking into a hospital should have to worry about is getting sicker while there. Yet, hospital-acquired infections are the most common complication of hospital care, claiming about 99,000 lives and costing the U.S. healthcare system about $30 billion each year.
Today's six stocks worth watching.
Shares in AstraZeneca rose sharply in London Wednesday after the drug company won a U.S. court ruling to protect a patent for its blockbuster cholesterol drug, Crestor.
Diabetes has become a pandemic of monumental proportion. Not only has it threatened the lives of millions, but it also has added to the massive economic burden of chronic disease.